Pharmacological management of persistent pain in older persons

Pain Medicine

Volumn 10, Issue 6, 2009, Pages 1062-1083

  Lckowicz, Elvy ^a  

^a American Geriatrics Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CANNABINOID; CAPSAICIN; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; EMLA; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; KETOROLAC; LIDOCAINE; MUSCLE RELAXANT AGENT; NABUMETONE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORCO; PARACETAMOL; PLACEBO; SALSALATE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICOSAL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; AGING; ANALGESIC ACTIVITY; ANDROGEN DEFICIENCY; ARTHROPATHY; BONE METASTASIS; BONE PAIN; BURNING SENSATION; CALCIUM BLOOD LEVEL; CANCER PAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAREGIVER BURDEN; CHRONIC PAIN; CHRONIC WOUND; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DIABETIC NEUROPATHY; DISEASE DURATION; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHORIA; ELDERLY CARE; ESOPHAGITIS; EVIDENCE BASED MEDICINE; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GIANT CELL ARTERITIS; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; HYPOCALCEMIA; LIBIDO DISORDER; LIVER TOXICITY; LONG TERM CARE; LOW BACK PAIN; LOW DRUG DOSE; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NONHUMAN; NURSING HOME; OSTEOARTHRITIS; PAIN ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHYSIOTHERAPY; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; QUALITY OF LIFE; RASH; RESPIRATION DEPRESSION; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SPASTICITY; UNSPECIFIED SIDE EFFECT;

EID: 70349620627     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00699.x     Document Type: Review

References (149)

1. Sternbach RA, Sternbach RA. Clinical aspects of pain. The Psychology of Pain 1978, 223-239. In, editor, New York, NY, Raven Press
2. Weiner D, Herr K, Weiner D, Herr K, Rudy T. Comprehensive interdisciplinary assessment and treatment planning: An integrative overview. Persistent Pain in Older Adults: An Interdisciplinary Guide for Treatment 2002, 18-57. In, eds, New York, Springer Publishing Company
3. Ferrell BA, Ferrell BR, Ferrell BA. Overview of aging and pain. Pain in the Elderly 1996, 1-10. In, editors, Seattle, IASP Press
4. He W, Sengupta M, Velkoff VA, et al. 65+ in the United States: 2005 2005, 23-209. ., Washington, DC, U.S. Census Bureau, Current Population Reports, U.S. Government Printing Office
5. Donald IP, Foy C. A longitudinal study of joint pain in older people. Rheumatology (Oxford) 2004, 43:1256-1260.
6. Helme RD, Gibson SJ. The epidemiology of pain in elderly people. Clin Geriatr Med 2001, 17:v-31.
7. Thomas E, Peat G, Harris L, et al. The prevalence of pain and pain interference in a general population of older adults: Cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). Pain 2004, 110:361-368. .
8. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: Fatigue, pain, and depression. J Natl Cancer Inst Monogr 2004, 32:150-157.
9. Potter J, Higginson IJ. Pain experienced by lung cancer patients: A review of prevalence, causes and pathophysiology. Lung Cancer 2004, 43:247-257.
10. Ferrell BA, Ferrell BR, Osterweil D. Pain in the nursing home. J Am Geriatr Soc 1990, 38:409-414.
11. Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995, 10:591-598.
12. The management of persistent pain in older persons. American Geriatrics Society. J Am Geriatr Soc 2002, 50:S205-24. AGS Panel on Persistent Pain in Older Persons
13. The management of chronic pain in older persons. American Geriatrics Society. J Am Geriatr Soc 1998, 46:635-651. AGS Panel on Chronic Pain in Older Persons
14. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians Task Force. Chest 2006, 129:174-181. .
15. Jaeschke R, Jankowski M, Brozek J, et al. How to develop guidelines for clinical practice. ., Minerva Anestesiol 2008 Nov 11. (Epub ahead of print
16. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2008, 148:141-146. .
17. Ferrell BA, Osterweil D, Brummel-Smith K, Beck JC. Pain. Comprehensive Geriatric Assessment 2000, 381-397. In, eds., New York, McGraw Hill
18. Helme RD, Katz B, Gibson SJ, et al. Multidisciplinary pain clinics for older people. Do they have a role?. Clin Geriatr Med 1996, 12:563-582. .
19. Stanos S, Houle TT. Multidisciplinary and interdisciplinary management of chronic pain. Phys Med Rehabil Clin north Am 2006, 17:435-450. vii
20. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain 2008, 1-101. American Pain Society, 6th, Ed., Glenview, American Pain Society
21. Buffum MD, Hutt E, Chang VT, et al. Cognitive impairment and pain management: Review of issues and challenges. J Rehabil Res Dev 2007, 44:315-330. .
22. Chibnall JT, Tait RC. Pain assessment in cognitively impaired and unimpaired older adults: A comparison of four scales. Pain 2001, 92:173-186.
23. Kaasalainen S, Crook J. A comparison of pain-assessment tools for use with elderly long-term-care residents. Can J Nurs Res 2003, 35:58-71.
24. Pautex S, Herrmann F, Le Lous P, et al. Feasibility and reliability of four pain self-assessment scales and correlation with an observational rating scale in hospitalized elderly demented patients. J Gerontol A Biol Sci Med Sci 2005, 60A:524-529. .
25. Taylor LJ, Harris J, Epps CD, et al. Psychometric evaluation of selected pain intensity scales for use with cognitively impaired and cognitively intact older adults. Rehabil Nurs 2005, 30:55-61. .
26. Herr K, Coyne PJ, Key T, et al. Pain assessment in the nonverbal patient: Position statement with clinical practice recommendations. Pain Manage Nurs 2006, 7:44-52. .
27. Hadjistavropoulos T, Herr K, Turk DC, et al. An interdisciplinary expert consensus statement on assessment of pain in older persons. Clin J Pain 2007, 23:S1-43. .
28. Delgado-Guay MO, Bruera E. Management of pain in the older person with cancer. Part 2: Treatment options. Oncology (Williston Park) 2008, 22:148-152. Discussion 152, 155, 160 passim
29. Fine PG. Opioid analgesic drugs in older people. Clin Geriatr Med 2001, 17:479-487.
30. Fine PG. Pharmacological management of persistent pain in older patients. Clin J Pain 2004, 20:220-226.
31. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8:287-313. .
32. Morone NE, Greco CM. Mind-body interventions for chronic pain in older adults: A structured review. Pain Med 2007, 8:359-375.
33. Weiner DK, Ernst E. Complementary and alternative approaches to the treatment of persistent musculoskeletal pain. Clin J Pain 2004, 20:244-255.
34. Chou R, Huffman LH. Medications for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007, 147:505-514.
35. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004, 63:901-907.
36. Abramson SB. Et tu, acetaminophen?. Arthritis Rheum 2002, 46:2831-2835.
37. Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 2002, 54:320-326. .
38. Wegman A, van der Windt D, van Tulder M, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. J Rheumatol 2004, 31:344-354. .
39. Kuffner EK, Temple AR, Cooper KM, et al. Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. Curr Med Res Opin 2006, 22:2137-2148. .
40. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial. JAMA 2006, 296:87-93. .
41. Wienecke T, Gotzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004, CD003789.
42. Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: A meta-analysis. Arthritis Rheum 2004, 51:746-754. .
43. Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, CD004257. .
44. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: Meta-analysis of randomised placebo controlled trials. BMJ 2004, 329:1317. .
45. Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008, CD000396. .
46. Bansal V, Dex T, Proskin H, et al. A look at the safety profile of over-the-counter naproxen sodium: A meta-analysis. J Clin Pharmacol 2001, 41:127-138. .
47. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf 2008, 31:545-556. .
48. Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002, 29:804-812. .
49. Boers M, Tangelder MJ, van Ingen H, et al. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: A pooled analysis of 12 randomised trials. Ann Rheum Dis 2007, 66:417-418. .
50. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003, 49:508-518. .
51. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: A consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63:759-766. .
52. April P, Abeles M, Baraf H, et al. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis?. Semin Arthritis Rheum 1990, 19:20-28. .
53. Cryer B, Goldschmiedt M, Redfern JS, et al. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology 1990, 99:1616-1621. .
54. Lanza F, Rack MF, Doucette M, et al. An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen. J Rheumatol 1989, 16:1570-1574. .
55. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001, 1:1.
56. McKellar G, Madhok R, Singh G. Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: Risks and benefits. Curr Opin Rheumatol 2008, 20:239-245.
57. Christensen S, Riis A, Norgaard M, et al. Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer. Aliment Pharmacol Ther 2007, 25:907-912. .
58. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001, 96:1019-1027. .
59. Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005, 7:R644-65. .
60. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006, 119:255-266. .
61. Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: Review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006, 7:79. .
62. Setakis E, Leufkens HG, van Staa TP. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum 2008, 59:1105-1111.
63. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol 2004, 31:2002-2012.
64. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: Systematic review and meta-analysis. BMC Musculoskelet Disord 2004, 5:28. .
65. Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004, 328:995. .
66. Hawkey CJ, Jones RH, Yeomans ND, et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007, 25:813-821. .
67. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, CD0022960. .
68. Hur C, Chan AT, Tramontano AC, et al. Coxibs versus combination NSAID and PPI therapy for chronic pain: An exploration of the risks, benefits, and costs. Ann Pharmacother 2006, 40:1052-1063. .
69. Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: A meta-analysis. Am J Med 2006, 119:448e427-36. .
70. Blandizzi C, Tuccori M, Colucci R, et al. Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. Drugs Aging 2008, 25:197-208. .
71. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 2007, 369:1621-1626. .
72. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: A randomised trial. Lancet 2002, 359:9-13. .
73. Giral A, Ozdogan O, Celikel CA, et al. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 2004, 19:773-777. .
74. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002, 359:14-22.
75. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005, 21:1411-1418. .
76. Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005, 165:490-496. .
77. Izhar M, Alausa T, Folker A, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004, 43:573-577. .
78. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001, 8:85-95. .
79. Juhlin T, Bjorkman S, Hoglund P. Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur J Heart Fail 2005, 7:1049-1056.
80. Niccoli L, Bellino S, Cantini F. Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis. Clin Exp Rheumatol 2002, 20:201-207.
81. Juhlin T, Bjorkman S, Gunnarsson B, et al. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 2004, 6:909-916. .
82. Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008, 101:1060-1063. .
83. Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007, 25:913-924. .
84. Singh G, Wu O, Langhorne P, et al. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: A meta-analysis. Arthritis Res Ther 2006, 8:R153. .
85. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J R Soc Med 2006, 99:132-140. .
86. Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 2007, 16:762-772.
87. Scott PA, Kingsley GH, Smith CM, et al. Non-steroidal anti-inflammatory drugs and myocardial infarctions: Comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007, 66:1296-1304. .
88. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308. .
89. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
90. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: A meta-analysis of randomized controlled trials. Osteoarthr Cartilage 2007, 15:957-965.
91. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007, 147:478-491. .
92. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005, 293:3043-3052.
93. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007, 12:13-21. .
94. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J 2007, 100:1028-1036.
95. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11:S5-62. .
96. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997, 13:6-8. American Academy of Pain Medicine and American Pain Society
97. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130. .
98. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999, 26:862-869. .
99. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999, 15:179-183. .
100. Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manage 2006, 2:155-166. .
101. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007, 132:237-251. .
102. Deshpande A, Furlan A, Mailis-Gagnon A, et al. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007, CD004959. .
103. Noble M, Tregear SJ, Treadwell JR, et al. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008, 35:214-228. .
104. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: A review of the evidence. Clin J Pain 2008, 24:469-478.
105. Chou R. Drug Class Review on Long-Acting Opioid Analgesics: Final Report 2008, 1-70. Portland, Oregon Evidence-based Practice Center, Oregon Health & Science University
106. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage 2003, 26:1026-1048.
107. Fine PG, Portenoy RK. Positioning Therapy and Patient Selection. A Clinical Guide to Opioid Analgesia 2007, 32-34. New York, Vendome Group LLC
108. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004, 112:372-380. .
109. Fishman SM, Wilsey B, Mahajan G, et al. Methadone reincarnated: Novel clinical applications with related concerns. Pain Med 2002, 3:339-348. .
110. Santiago TV, Edelman NH. Opioids and breathing. J Appl Physiol 1985, 59:1675-1685.
111. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002, 3:377-384.
112. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res 2006, 6:46. .
113. Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002, 17:173-179. .
114. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain 2006, 22:667-676. .
115. Jovey RD, Ennis J, Gardner-Nix J, et al. Use of opioid analgesics for the treatment of chronic noncancer pain-a consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 2003, 8(A):3A-28A. ., Suppl
116. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007, 23:103-118. .
117. Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/ addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008, 9:444-459. .
118. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain 2005, 6:107-112. Pain Med
119. Model Policy for the Use of Controlled Substances for the Treatment of Pain 2004, 1-5. Federation of State Medical Boards, Dallas, Federation of State Medical Boards (FSMB)
120. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006, 9:1-39. .
121. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med 2005, 6:432-442.
122. Butler SF, Fernandez K, Benoit C, et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008, 9:360-372. .
123. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain 2007, 130:144-156. .
124. Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic noncancer pain. Pain 2007, 129:355-362. .
125. Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998, 41:1603-1612.
126. Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: Approaches to correcting the problem. Drugs Aging 2005, 22:641-654.
127. Portenoy RK, Doyle D, Hanks GW, MacDonald N. Adjuvant analgesics in pain management. Oxford Textbook of Palliative Medicine 1998, 361-390. In, eds., 2nd, Ed., New York, Oxford University Press
128. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998, 280:1831-1836. .
129. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000, 55:S54-8. Discussion
130. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998, 280:1837-1842. .
131. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007, CD005454.
132. Shneker BF, McAuley JW. Pregabalin: A new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005, 39:2029-2037.
133. Wiffen PJ, McQuay HJ, Edwards JE, et al. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005, CD005452. .
134. Lussier D, Portenoy RK, Douyle D, Hanks G, Cherny N, et al. Adjuvant analgesics in pain management. Oxford Textbook of Palliative Medicine 2004, 349-378. In, , eds., 3rd, Ed., New York, Oxford University Press
135. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994, 9:442-445.
136. Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 1994, 9:500-509.
137. Reddy S, Patt RB. The benzodiazepines as adjuvant analgesics. J Pain Symptom Manage 1994, 9:510-514.
138. Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997, 275:112-114. .
139. Roth A, Kolaric K. Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. Oncology 1986, 43:283-287.
140. Gralow J, Tripathy D. Managing metastatic bone pain: The role of bisphosphonates. J Pain Symptom Manage 2007, 33:462-472.
141. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007, CD004846.
142. Stow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia. Efficacy and pharmacokinetic profile. Pain 1989, 39:301-305.
143. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004, 328:991. .
144. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994, 46:517-522.
145. Moore RA, Tramer MR, Carroll D, et al. Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998, 316:333-338. .
146. Tramer MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: A qualitative systematic review. Acta Anaesthesiol Scand 1998, 42:71-79. .
147. Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007, 23:17-24. .
148. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. JAMA 2003, 290:1757-1762. .
149. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008, 9:506-521. .